Internalization and nuclear localization of interleukin 1 are not sufficient for function - PubMed (original) (raw)
Affiliations
- PMID: 1664234
Internalization and nuclear localization of interleukin 1 are not sufficient for function
A Heguy et al. Cell Growth Differ. 1991 Jul.
Abstract
The human fibroblast interleukin 1 (IL-1) receptor is a glycosylated transmembrane protein with a cytoplasmic domain of 213 amino acids. We have constructed a series of deletion mutants of the cytoplasmic region of the IL 1 receptor and have used these mutants to examine its role in ligand binding, internalization, signal transduction, and nuclear localization of IL-1. Mutant receptors lacking most of the cytoplasmic domain are expressed at the cell surface and can bind, internalize, and localize IL-1 at the nucleus, but they do not allow IL-1-mediated induction of interleukin 2 and SV40 promoters. We have localized a critical region for signal transduction to a 50-amino acid segment of the cytoplasmic domain of the receptor. These studies demonstrate that IL-1 internalization and nuclear localization are not sufficient to trigger IL-1 activation of gene expression in T-cells.
Similar articles
- The interleukin 1 receptor. Dynamics of interleukin 1 binding and internalization in T cells and fibroblasts.
Mizel SB, Kilian PL, Lewis JC, Paganelli KA, Chizzonite RA. Mizel SB, et al. J Immunol. 1987 May 1;138(9):2906-12. J Immunol. 1987. PMID: 2952728 - IL-1 and its receptor are translocated to the nucleus.
Curtis BM, Widmer MB, deRoos P, Qwarnstrom EE. Curtis BM, et al. J Immunol. 1990 Feb 15;144(4):1295-303. J Immunol. 1990. PMID: 2137488 - Interleukin-1 and its receptor.
Dinarello CA, Savage N. Dinarello CA, et al. Crit Rev Immunol. 1989;9(1):1-20. Crit Rev Immunol. 1989. PMID: 2523282 Review. - [Function, molecular structure and gene expression of interleukin-1].
Kasahara T, Kuno K, Matsushima K. Kasahara T, et al. Nihon Rinsho. 1992 Aug;50(8):1769-75. Nihon Rinsho. 1992. PMID: 1433966 Review. Japanese.
Cited by
- Dual functionality of interleukin-1 family cytokines: implications for anti-interleukin-1 therapy.
Luheshi NM, Rothwell NJ, Brough D. Luheshi NM, et al. Br J Pharmacol. 2009 Aug;157(8):1318-29. doi: 10.1111/j.1476-5381.2009.00331.x. Br J Pharmacol. 2009. PMID: 19681864 Free PMC article. Review. - Toll-like receptors and chronic inflammation in rheumatic diseases: new developments.
Joosten LA, Abdollahi-Roodsaz S, Dinarello CA, O'Neill L, Netea MG. Joosten LA, et al. Nat Rev Rheumatol. 2016 Jun;12(6):344-57. doi: 10.1038/nrrheum.2016.61. Epub 2016 May 12. Nat Rev Rheumatol. 2016. PMID: 27170508 Review. - Interleukin-1 in the pathogenesis and treatment of inflammatory diseases.
Dinarello CA. Dinarello CA. Blood. 2011 Apr 7;117(14):3720-32. doi: 10.1182/blood-2010-07-273417. Epub 2011 Feb 8. Blood. 2011. PMID: 21304099 Free PMC article. Review. - Structure-function analysis of the tobacco mosaic virus resistance gene N.
Dinesh-Kumar SP, Tham WH, Baker BJ. Dinesh-Kumar SP, et al. Proc Natl Acad Sci U S A. 2000 Dec 19;97(26):14789-94. doi: 10.1073/pnas.97.26.14789. Proc Natl Acad Sci U S A. 2000. PMID: 11121079 Free PMC article.